Six research engines and three distinct hedge methodologies, unified by one permanent institutional memory across equities, crypto, options, market structure and deep fundamental underwriting.
Find the information ladder before the validating headline: prior proof, regulator/customer/government validation, catalyst proximity, incomplete repricing and asymmetric upside.
Find $1B+ liquid stocks before major repricing using catalyst quality/timing, relative-volume acceleration, attention acceleration, technical structure, relative strength, sector regime, asymmetry and remaining repricing.
Merge pre-repricing catalyst intelligence with high-conviction technical execution to build a liquid 15-asset portfolio for an emerging crypto risk-on cycle.
Find $1B+ companies where billion-dollar institutional positioning, crowded shorts, forced liquidation or whale timing errors collide with a catalyst capable of proving the dominant bet wrong.
Measure what options traders are paying for on the put side versus the call side, then cross that positioning against price, volume, sector context and AETHRON execution systems.
Check the health and forward positioning of every tracked stock by separating high-quality analyst signal from noise, reading elite-fund rotation, measuring technical/catalyst health, and comparing Street targets with AETHRON's own bull/base/bear forecast.
Independently vet any equity from the ground up. Enter a ticker such as NVDA and rebuild its economics, concentration map, normalized earnings, peer valuation, earnings drivers, Bear/Base/Bull values, reverse DCF, thesis-failure tests and standardized scorecard—without requiring Situational Hedge 0.1, 0.2, Kelvin, MAX WILD or any other AETHRON methodology.
Moderna-move inspired methodology: identify companies where multiple pieces of public evidence already point toward a consequential future event, while the equity has not yet fully repriced that probability.
Strong prior evidence → durable validation → regulatory support → mature Phase 3 → final validating event → violent platform repricing. The goal is to locate the equivalent ladder before the final headline.
Strength, durability and replication of preceding evidence.
How near and date-certain the validating event is.
FDA, government, major customer, partner, contract or independent validation.
How much of the success case is still absent from the stock price.
Potential magnitude if the final evidence validates the thesis.
Ability to enter/exit without the setup becoming untradeable.
Whether we can define an objective pre-event entry condition.
| # | Ticker | Sector | Price Snapshot | Catalyst Score | Class | Next Catalyst | Timing | Repricing | Research |
|---|
Kelvin Xu-inspired, AETHRON-upgraded methodology for finding fundamentally credible, liquid stocks before major repricing occurs, where attention, volume, catalyst timing and technical structure are beginning to align. The system asks: What stock is the market likely to care substantially more about 5–60 days from now than it cares about today?
DISCOVER EARLY. ENTER WITH ASYMMETRY. WAIT WITH CONVICTION. EXIT WHEN THE THESIS CHANGES. ROTATE CAPITAL. NEVER FORCE THE TRADE.
Below $1B = REJECT. $1B–$3B = high asymmetry. $3B–$10B = PRIME ZONE. $10B–$50B acceptable. $50B+ requires a catalyst powerful enough to move a larger company.
Evaluate average daily dollar volume, share volume, spread, institutional participation, intraday liquidity and abnormal-volume capacity. Thinly traded stocks fail.
No meaningful catalyst = WATCH, NOT ENTER. Catalysts include earnings inflection, customers, contracts, policy, product, funding, shortages, capacity, AI demand or technological transition.
Ask: has the market already discovered what we discovered? Price explosion, volume climax, euphoric attention and consensus upgrades are downgrades or vetoes.
13–15 company-changing • 10–12 material • 7–9 moderate • 0–6 weak/speculative.
9–10 = 0–30 days • 7–8 = 30–60 • 4–6 = 60–120 • 0–3 unclear or too distant.
Relative volume at the current time of day versus expected volume, 5/20/50-day norms, dollar volume, up/down volume and intraday acceleration.
Rate of change across financial media, X, Reddit, search interest, StockTwits, analysts, executives and industry chatter.
Major support, multi-month base, higher low, tight consolidation, seller exhaustion, MA reclaim, compression, breakout retest or failed breakdown.
Compare against S&P 500, Nasdaq, sector ETF, industry peers and closest competitors.
Broad trend, rates, dollar, credit, volatility, sector flows, commodities and risk-on/risk-off environment.
Highest score = strong thesis + weak current recognition. A great story with most of the move already completed is downgraded.
Compare realistic upside with downside; generally favor plausible reward/risk of at least ~3:1.
What remains if the catalyst takes longer? Favor fundamentals, balance sheet, secular demand, strategic assets and competitive advantage.
Exceptional setup. Rare. Strong candidate for capital deployment.
High conviction. Potential entry with disciplined sizing.
Strong setup but one component still needs confirmation.
Interesting but incomplete. No forced trade.
Needs significant improvement.
Capital belongs somewhere else.
The stock already made its major move. CHASED = do not enter.
Great story, nobody buying. WAIT.
If the fundamental reason for the trade disappears: EXIT.
Good thesis, but capital may be trapped waiting. Downgrade.
FDA, court, earnings, regulatory vote, merger decision. Explicitly classify PRE-CATALYST vs THROUGH-EVENT.
AETHRON must be able to say NO TRADE. Cash is valid.
Severe macro conditions can override individual-stock quality.
Price close to validated support while thesis improves. Highest asymmetry.
Breakout confirms, then former resistance holds as support.
Build before a known catalyst while technical structure remains favorable.
Unexpected volume appears before obvious news/price expansion. Investigate before execution.
Core Kelvin 0.2 methodology = shares. Options are a separate tactical overlay, not presented as Xu's strategy.
Concentration already magnifies volatility; borrowed capital adds unnecessary liquidation risk.
Price stop: technical structure breaks. Thesis stop: the reason we entered no longer exists.
“IS THE REASON WE BOUGHT THIS STILL TRUE?” YES = hold/manage. UNCERTAIN = reduce/watch. NO = exit.
Benefit from anticipation/repricing before the event.
Higher-risk; requires explicit justification for earnings, FDA, lawsuits, votes or other binary outcomes.
Supply chains, government spending, customer announcements, competitors, capex, shortages, products, earnings calls, procurement, policy, contracts, conferences and executive interviews.
Ask: what consequence of public information has the market not priced yet?
Attention ↑, Volume ↑, Catalyst ↑, Price flat = investigate aggressively.
Attention extreme + volume extreme + price parabolic = likely repricing already underway/completed.
| # | Ticker | Research Group | Historical Price | Historical Score | Legacy Classification | Current Action | Original Research | Vault |
|---|
Purpose: identify rare situations where the market contains a large, observable institutional bet — crowded short interest, a concentrated whale long, forced liquidation, activist ownership, or a rescue/block-trade dislocation — and the underlying company has a credible product, operating or regulatory catalyst that can make the dominant positioning fail. The edge is not “hedge funds are stupid.” The edge is finding when their timing, leverage, forced flow or consensus assumption can be wrong before the business evidence resolves.
| # | Ticker | MAX WILD | Classification | Scarcity Lane | Supply Score | Positioning / Dislocation | Contradiction Catalyst | Current MAX WILD Route |
|---|---|---|---|---|---|---|---|---|
| 1 | COHU | 92 | ELITE WILD BET | AI/HPC semiconductor test + precision thermal control | 4 / 5 | Heavy short crowd versus rising AI/HPC test demand and high test-cell utilization. | Next-gen AI datacenter processor orders + continued utilization/revenue proof can break the semi-cap bear thesis. | SYSTEM 04 PRIORITY • WAIT FOR TRIGGER |
| 2 | CAMT | 91 | ELITE WILD BET | Advanced packaging / HBM inspection & metrology | 5 / 5 | Meaningful short positioning while advanced-packaging and HBM order flow accelerates. | HBM / 2.5D / 3D inspection orders and AP revenue conversion can contradict a packaging-capex peak thesis. | SYSTEM 04 PRIORITY • WAIT FOR TRIGGER |
| 3 | POWL | 90 | ELITE WILD BET | Switchgear / electrical distribution / behind-the-meter power | 5 / 5 | Rising short interest against record orders, backlog and data-center electrical demand. | Backlog conversion and new data-center awards can prove power scarcity is structural rather than a cyclical peak. | SYSTEM 04 PRIORITY • WAIT FOR SETUP |
| 4 | AMRC | 89 | STRONG WILD BET | Grid-queue bypass / behind-the-meter generation | 5 / 5 | Large short crowd versus rapidly expanding data-center power awards and backlog. | Awards converting into contracted backlog / construction milestones can force a financing-and-execution consensus reset. | SYSTEM 04 • FINANCING VETO ACTIVE |
| 5 | AAON | 89 | STRONG WILD BET | Hyperscale data-center cooling | 5 / 5 | Large valuation reset despite sharply expanding sales and backlog. | Cooling-capacity ramp and BASX backlog conversion can expose an overdone de-rating. | SYSTEM 04 • HIGH-PRIORITY WATCH |
| 6 | AMSC | 88 | STRONG WILD BET | Grid reliability / power quality / utility interconnection | 4 / 5 | Short positioning plus price de-rating while grid bookings/backlog expand. | Utility/data-center grid demand can reframe bookings from cyclical to structural scarcity. | SYSTEM 04 • WATCH FOR PROOF |
| 7 | MOD | 86 | STRONG WILD BET | Data-center thermal management / cooling capacity | 5 / 5 | Short interest rising while supply constraints limit shipment into strong demand. | Capacity expansion and backlog conversion can prove current bottlenecks are deferred revenue, not demand destruction. | SYSTEM 04 • WAIT FOR CAPACITY PROOF |
| 8 | BELFB | 84 | WILD WATCH | Power conversion / magnetics / high-speed connectivity | 4 / 5 | Moderate short crowd after a large rerating; still enough disagreement to monitor. | Further data-center power/connectivity acceleration must prove the mix shift is durable. | PROOF TRANCHE ONLY |
| 9 | ACLS | 83 | WILD WATCH | Ion implantation / memory & power semiconductor fab capacity | 4 / 5 | Short crowd has already partially capitulated, reducing squeeze convexity. | Memory demand, backlog and transaction/event milestones need a new dislocation before Wild capital qualifies. | WAIT FOR NEW DISLOCATION |
| 10 | GNRC | 82 | WILD WATCH | On-site generation / speed-to-power for data centers | 5 / 5 | Low squeeze fuel, but legacy residential framing may underweight emerging data-center exposure. | Data-center backlog conversion and capacity expansion must become material enough to change the earnings mix. | CATALYST CONFIRMATION |
Below $1B = reject from MAX WILD. We want companies large enough for institutional capital and liquid options/shares.
At least one: large aggregate short interest, material 13F/13D/13G long, disclosed put/call exposure, forced block liquidation, activist/strategic stake or manager disclosure.
A real event must be capable of invalidating the crowded thesis within a practical horizon: product, trial, contract, launch, financing, profitability, regulatory or customer milestone.
The company must have enough liquidity, financing and operational runway to reach the event without probable insolvency or destructive dilution.
Enough share and options liquidity to enter/exit. Wide-spread, manipulated or untradeable names fail regardless of story.
AETHRON must state exactly which assumption, timing error, forced flow or business-development surprise can break the dominant positioning.
Short crowd, concentrated whale long, forced liquidation, option crowding or institutional ownership conflict.
SEC filing / FINRA / exchange / manager disclosure / documented block trade beats rumor.
How powerfully can the next event disprove the market's dominant assumption?
Evidence already exists before the wild event: revenue, customer, technology, trial, contract or deployment proof.
Best: 0–60 days. Accept 60–180 only with enough runway and low carry cost.
Days-to-cover, float, borrow stress, margin-call selling, block trades, option gamma and trapped positioning.
Wild bets fail when discovered too late. We want the contradiction before the crowd capitulates.
Can the company reach the catalyst without financing destroying the thesis?
Tight enough spreads, OI and expiration depth for defined-risk execution.
Attention and volume start moving before price becomes obviously parabolic.
Small known premium risk against a plausible nonlinear repricing path.
Rare $1K Wild Unit candidate — still requires trigger.
Institutional conflict + catalyst + convex mechanics converge.
One key element still needs confirmation.
Research aggressively, no wild capital yet.
Keep as case study / route to another AETHRON methodology.
Large short base + product/fundamental proof + approaching catalyst. Moderna-style squeeze dynamics.
A whale was overlevered/wrong on timing; forced selling creates a discount while business thesis survives. Situational Awareness → Citadel archetype.
Large disclosed fund concentration appears early and company evidence begins validating the non-consensus thesis.
Large disclosed puts or bearish positioning collides with an unexpected positive event.
13D/13G strategic stake plus operational catalyst creates a second source of pressure on the market's thesis.
Company is dumped with its sector/fund despite company-specific proof remaining intact.
Quarter-end snapshot, delayed. Great for concentration and changes; not a live portfolio.
Stronger signal for material ownership and strategic/activist stakes.
Aggregate open shorts reported twice monthly. Does not identify the individual fund.
SEC Rule 13f-2 / Form SHO adds aggregated substantial short-position information.
Documented prime-broker rescue, block trades and margin-call flows can reveal price pressure unrelated to fundamentals.
X/Twitter and message-board claims are discovery signals only. They never satisfy the whale-evidence gate alone.
No wild thesis built on “Fund X is short” without evidence.
Lockups, convert hedges, low float and denominator disagreements can create fake squeeze signals.
If shorts capitulated and price went parabolic, the wild opportunity is over.
Probable insolvency/destructive dilution before catalyst overrides all squeeze potential.
High short interest alone is not a thesis.
No 0DTE / ultra-short-dated far-OTM bet masquerading as research.
If we cannot state what the market/fund is wrong about, we do not bet.
Only after evidence gate + technical trigger. Can be shares or long-dated defined-risk option.
Add only when volume/attention/price confirm the contradiction is entering the market.
Deploy only when catalyst timing, liquidity and option structure align. Maximum loss known at entry.
Do not add because premium is cheaper. Add only because evidence improved.
Strongly consider removing the original $1,000 risk once the position doubles.
Take another portion; stop turning exceptional paper gains back into zero.
Harvest progressively while preserving a small runner.
Only a small residual position is allowed to pursue 25×–100×+ or extreme 1,000× tails.
Green = bullish. We are betting that the shorts / forced sellers are wrong, so the trade is normally SHARES or a CALL after confirmation. Red = bearish. When MAX WILD eventually finds a bearish setup, the default is a PUT — not a naked short — because a put has a known maximum loss. WAIT means do nothing with money yet.
| Ticker | Direction | DO THIS NOW | If Trigger Happens | Entry Window | How Long | Review / Exit Clock | Simple Trigger | Simple Stop |
|---|
| # | Ticker | Score | Classification | Archetype | Market Cap Gate | Institutional / Short Conflict | Catalyst | Decision Window | Action |
|---|
The lesson is not “buy every heavily shorted stock.” It is what happens when positioning is crowded, float/flow becomes reflexive and a catalyst/narrative forces covering.
Before the Aug. 19 repricing, Moderna had substantial short interest; positive Phase 3 oncology data then collided with bearish positioning. Completed repricing benchmark, not a current wild entry.
A huge concentrated AI book can be directionally intelligent and still fail catastrophically because leverage and timing force liquidation before thesis maturity.
Buying a distressed portfolio at a discount and rapidly distributing risk demonstrates the opportunity created when price is driven by forced balance-sheet mechanics rather than fresh company information.
Purpose: identify stocks where the options chain is paying materially more for upside or downside than price alone would suggest. The system measures mirrored out-of-the-money put/call implied volatility, crosses it with the stock's 21-trading-day return, then ranks the resulting price-versus-positioning disagreement. This is a positioning map, not a standalone entry signal.
Price is falling while traders pay up for upside. This is the most important disagreement on the map.
AETHRON: WATCH FOR CALL — never buy from skew alone.
Price and options traders agree bullishly. The trade may work, but the entry is more crowded and later.
AETHRON: NO NEW CALL / DON'T CHASE.
Price is rising while protection remains expensive. The rally is not fully trusted underneath.
AETHRON: HOLD / TIGHTEN if already owned.
Price and protection agree bearishly. Falling plus increasingly expensive insurance is not automatically a bargain.
AETHRON: LEAVE ALONE until evidence changes.
Use the OTM put nearest −0.25 delta and OTM call nearest +0.25 delta. Probability distance, not dollar distance.
Use the standard monthly expiry nearest 45 calendar days, only if it falls 30–60 DTE. Otherwise use the next standard monthly inside the range.
Normalized skew ranks stocks within comparable groups. Raw IV-point difference is retained for cross-sector comparison.
Ranking universe = AETHRON stock systems + fresh discoveries. Sector benchmarks = separate broad neutral sector cohorts, never the AETHRON watchlist itself.
Do not silently delete thin chains. Give every row a quality score/grade and reduce its ranking influence. Truly unusable chains become DATA FAIL and remain visible.
Initial AETHRON quarantine rule: |normalized skew| above 0.75 is rejected for scoring and manually checked for a bad quote. Recalibrate only after enough history, never to rescue a favorite name.
Store one row per ticker per run from the first day. Five-day change becomes useful quickly; 20-day change and normalized history require time.
Do not use whole-chain SPY/QQQ/IWM put/call ratios as sentiment. Tail hedges make the answer heavily dependent on arbitrary strike windows.
Cross-sector fear comparison uses raw volatility points. Normalized skew can make low-IV sectors look falsely extreme.
Never call a sector fearful/bullish from an average alone. Show the share of constituents leaning the same way and caveat low agreement.
Filter bad marks per leg, then apply the sanity ceiling. One option quote is not allowed to invert a stock or sector conclusion.
If earnings or another dated catalyst sits inside the measured expiry, flag EVENT-CONTAMINATED and compare against a later monthly before reading the skew as positioning.
Contrarian Bid receives the highest bullish research priority because price and call positioning disagree.
Change versus 5 trading days and 20 trading days. The level is structural; the change is the signal.
Where the name's skew sits inside its own sector, not against unrelated industries.
Official map uses raw 21-day return; the ranking also keeps return minus SPY to avoid confusing a bull market with stock-specific strength.
RVOL and dollar-volume context. Heavy participation strengthens a developing positioning change.
Mirrored deltas, reliable marks, sufficient depth and consistent expiry. Poor quality down-weights rather than silently disappearing.
No near-term earnings/catalyst distortion inside the selected expiry, or a later-expiry comparison confirms the same positioning.
Catalyst 0.1, Kelvin 0.2 or MAX WILD 0.4 independently supplies the chart/catalyst reason to care.
High-quality Contrarian Bid + rapidly improving call skew + separate AETHRON confirmation. Immediate chart/catalyst research.
Strong positioning disagreement; one confirmation layer still missing.
Interesting change, but not yet strong enough for an options decision.
No positioning edge or too much noise.
Bad quote, unusable chain, event contamination unresolved, or mismatched expiry. Never score it.
| # | Ticker | Sector / Theme | Why It Is On System 05 | Cross-Engine | Options Data | Current System 05 Action |
|---|
| Ticker | Sector | ATM IV | 25Δ Put IV | 25Δ Call IV | Norm Skew | Raw Vol Pts | Δ 5D | Δ 20D | 21D Return | vs SPY | RVOL | Sector %ile | Quality | Event? | Quadrant | Action |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| The 10-stock System 05 universe is loaded. Live quadrant/skew values remain blank until AETHRON reads a verified 30–60 DTE monthly chain with per-contract IV + delta. First post-close read is scheduled for Monday, Aug. 24. No values are invented. | ||||||||||||||||
A 17-asset crypto portfolio merging Catalyst Swing Watch 0.1 and AETHRON Kelvin Strategy 0.2. The objective is not to own every popular token: it is to own projects where real adoption, an evidence/catalyst ladder, liquidity, relative strength, token value capture and incomplete repricing converge before the strongest phase of a crypto risk-on cycle.
BTC has surged into the upper-$70Ks and ETH/major alts have repriced sharply in only a few sessions. AETHRON treats the move as constructive but extended: tokenization leaders are LONG-BIAS assets, yet the current action is WAIT for pullback/retest or a clean breakout confirmation rather than chase.
| # | Token | Tokenization Score | Role | Price Snapshot | Do Now | Long Position? | BUY ONLY IF | SELL / Stop | Expected Hold | Review |
|---|
| # | Stock | Tokenization Score | Role | Crypto / Rail Exposure | Current Status | Bias | BUY ONLY IF | SELL / Exit | Expected Hold |
|---|
Usage, TVL, volume, revenue, integrations and developer/product traction.
Protocol upgrade, regulation, institutional launch, distribution or adoption milestone.
Institutional, regulatory, ecosystem, fund-flow or strategic validation.
Potential upside not yet reflected in market capitalization and narrative saturation.
Supply, unlocks, staking/burn/buyback utility and whether network growth can benefit the token.
Depth, volume and ability to scale in/out of positions without micro-cap execution risk.
Leadership versus BTC, ETH and the relevant crypto sector.
Higher lows, bases, breakout/reclaim quality and objective invalidation.
Does current capital flow support the project's theme?
Upside potential after accounting for dilution, protocol and cycle risk.
| # | Asset | Theme | Price Snapshot | Fusion Score | Catalyst 50 | Conviction 50 | Target Weight | Current Action | Next Catalyst |
|---|
SOL 14% • ETH 12% • BTC 8% • LINK 9%
HYPE 9% • AAVE 6% • ONDO 8% • JUP 3%
TAO 6% • NEAR 4% • RENDER 3% • QUBIC 2%
SUI 4% • AVAX 5% • XLM 3% • SEI 1%
ENA 3% — satellite only because structural risk is higher.
Street opinion is not accepted at face value. Market Health 0.6 weights analysts by demonstrated historical performance, separates firm-level reputation from individual analyst edge, overlays elite-investor portfolio rotation, then compares those external signals with AETHRON's catalyst, technical, repricing and risk work. The output is a health score, bull/base/bear lean, execution posture and a visible Grey-Area Gap between Street consensus and AETHRON's independent base case.
Success rate, average return, sample quality and stock-specific historical edge.
New positions, increases, reductions and exits from high-quality disclosed managers.
Trend, abnormal volume, technical structure and attention acceleration.
Revenue/earnings inflection, event timing, validation and business-quality trend.
How much upside remains versus what the market and consensus already discount.
Overextension, event/binary risk, balance-sheet risk and thesis crowding.
Choose any AETHRON sector, select exactly three stocks, and run the same cross-source health analysis. Exit the analysis to choose another sector and repeat.
| Source | Success | Avg Return | Best Call | AETHRON Status | Use |
|---|
| # | Ticker | Company | Sector | Health | Lean | Street | Smart Money | Current | Street Avg | AETHRON Base | Grey Gap | Current Action | Systems | Open |
|---|
Robinhood stocks synchronize through Plaid Investments. Crypto holdings, fills and marks use Robinhood's official Crypto Trading API. Broker executions remain separate from system signals for clean performance attribution.
Credentials remain server-side. The browser never receives Plaid access tokens or your Robinhood crypto private key.
| Asset | Type | Qty | Avg Cost | Price | Market Value | Unrealized P&L | Unrealized % | Source |
|---|
| Date | Asset | Type | Side | Qty | Price | Fees | Source |
|---|
This is the calendar layer above both stock methodologies. A date is a decision window, not an automatic purchase date. AETHRON buys only when the dated window and the required price/volume/thesis trigger converge. If the condition is absent by the reassessment date, the stock is re-scored rather than forced.
| System | Ticker | Research Status | Buy / Decision Window | Confirmation / Add | Catalyst / Event | Next Reassessment | BUY ONLY IF | DO NOT BUY IF | Expected Hold |
|---|
Track where policy power and actual capital overlap: congressional votes and sponsorship, public STOCK Act disclosures, crypto-linked equities, campaign/PAC flows, White House executive access, corporate treasury activity and strategic investments. This is an evidence overlay for AETHRON's three investment engines — not a substitute for price, fundamentals or token value capture.
A favorable speech is weak. A recorded vote is stronger. A disclosed purchase, customer/investment commitment or large capital allocation is stronger still. The highest-confidence signal is convergence — but public financial disclosures can arrive up to 45 days after a transaction.
| Score | Lawmaker | Chamber | Policy Signal | Public Money Signal | Assets | AETHRON Read | Source |
|---|
| Score | Executive / Firm | Policy Access | Political Capital | What the Firm Is Actually Funding / Building | Investable Implication | Source |
|---|
All House/Senate roll calls on CLARITY, GENIUS, CBDC, Bitcoin reserve, staking, stablecoins and market structure.
Direct crypto, spot ETFs and crypto proxies: COIN, MSTR, HOOD, CRCL, miners, exchanges and infrastructure.
Fairshake, Protect Progress, Defend American Jobs, company/founder contributions and candidate beneficiaries.
White House, SEC, CFTC, Treasury and congressional meetings involving crypto CEOs and major TradFi executives.
BTC/ETH/token purchases and sales, reserves, staking, stablecoin balances and digital-asset treasury changes.
Acquisitions, venture investments, chain deployments, tokenization rails and institutional partnerships.
Translate money flows into token-specific implications only where there is plausible value capture.
Flag when rhetoric says BUY while disclosed/corporate money says SELL — often the most important signal.
Coinbase's USDC treasury deployment on Hyperliquid plus direct White House attention creates a rare intersection of institutional capital infrastructure and regulatory-access signals. This strengthens HYPE's research score, but does not justify chasing a vertical price move.
Ripple is one of the industry's largest political spenders, its CEO has high-level access, and Ripple is investing into XRP-Ledger tokenization infrastructure. XRP now deserves a full Crypto Fusion re-score and could challenge the weakest portfolio satellite if tokenomics and technical structure confirm.
Congressional BTC ownership and strategic-reserve legislation remain bullish policy evidence. But Strategy has recently sold BTC to fund obligations, and Trump's disclosures showed substantial crypto-derived wealth moved into stocks and bonds. Do not equate political support with universal institutional accumulation.
Kraken/xStocks and Robinhood's onchain expansion give both networks real institutional-finance relevance. SOL gets additional direct congressional-trade history; ETH gets repeated congressional buying history and Robinhood Chain L2 exposure.
All researched stocks and crypto assets are stored here once and retained even when their score changes, a catalyst passes, or they fall out of the active top rankings. Use the global search at the top of every screen to find any ticker or company instantly. Kelvin-stock legacy scores remain historical; fresh System 02 reviews use Kelvin Strategy 0.2. Every tracked equity also receives the System 06 Market Health 0.6 overlay for analyst quality, smart-money rotation, forward health and AETHRON-vs-Street forecast divergence.
| Ticker | Market-Cap Gate | AETHRON Destination | Current Action | Reason |
|---|---|---|---|---|
| TEM | PASS • $1B+ | System 02 • Kelvin 0.2 • High-Conviction + System 06 Health 0.6 | WAIT FOR ENTRY | 88/100. AI diagnostics + MRD + data-licensing acceleration; buy only on quality pullback or confirmed breakout. |
| RLAY | PASS • ~$4B | System 02 + System 04 • MAX WILD + System 06 Health 0.6 | WAIT FOR BREAKOUT | 87/100. Precision-oncology catalyst convexity; >$20.79–$21.30 confirmation or $19–$20 retest/reclaim. |
| NTRA | PASS • ~$48B | System 02 • Tier-1 Pullback + System 06 Health 0.6 | WAIT / DO NOT CHASE | 80/100. A+ business quality, but current price is extended and much of the repricing has occurred. |
| EQIX | PASS • large-cap | Economic Cycle + Kelvin 0.2 Queue | RESCORE / WAIT | AI data-center/interconnection demand; Q2 guidance raised. |
| LRCX | PASS • ~$393B | Economic Cycle + Kelvin 0.2 Queue | RESCORE / WAIT | AI wafer-fab demand; strong earnings, but repricing/valuation must be tested. |
| ENTG | PASS • ~$21B | Economic Cycle + Kelvin 0.2 Queue | RESCORE / WAIT | Advanced semiconductor materials; AI-manufacturing beneficiary. |
| BWXT | PASS • ~$13.7B | Economic Cycle + Kelvin 0.2 Queue | RESCORE / WAIT | Nuclear + defense structural demand. |
| TDG | PASS • ~$66B | Economic Cycle + Kelvin 0.2 Queue | RESCORE / WAIT | Aerospace aftermarket pricing power; leverage/valuation need discipline. |
| INDI | CAP FAIL • ~$904M | Catalyst Swing Watch 0.1 | CATALYST CANDIDATE | Q2 revenue +24%, Q3 guide ~30%, radar OEM adoption expanding. |
| APRE | CAP FAIL • ~$8M | MAX WILD 0.4 SHADOW EXCEPTION | RESEARCH ONLY | APR-1051 oncology catalyst is real, but standard MAX WILD capital is prohibited by the $1B gate. |
Every stock and crypto tracked anywhere inside AETHRON now routes into one permanent audit ledger. Historical baselines are immutable, current/live marks refresh separately, and research movement never becomes an AETHRON return unless the original entry trigger actually fired.
The Recorded Price is frozen when the research record is created. The Current Mark is refreshed when live data is available and otherwise shows the latest independently verified snapshot with its timestamp. Market movement is not counted as an AETHRON trade return unless the system's entry trigger actually fired.
| Asset | Methodology | Baseline Status / Date | Recorded Price | Current / Live Price | Move Since Baseline | AETHRON Action Then | Signal Return? | Mark Source |
|---|
Baseline established from the verified Robinhood read-only account review on Aug. 21, 2026. Scheduled AETHRON runs now request Robinhood portfolio, realized P&L and trade-history data in read-only mode and report only material deltas.
| Account | Type | Trading Type | Account Value | Cash | Buying Power | AETHRON Role |
|---|---|---|---|---|---|---|
| Default | Individual | Margin | $239.12 | $0.36 | $0.36 | Read-only legacy portfolio |
| Agentic | Individual | Limited margin | $96.61 | $68.48 | $68.48 | AETHRON execution account |
| Managed | Individual, managed | Limited margin | $0.00 | $0.00 | $0.00 | Read only |
| Traditional IRA | IRA | Limited margin | $0.00 | $0.00 | $0.00 | Read only |
| Asset | Account | Class | Methodology | Qty | Avg Cost | Cost Basis | Current / Latest | Market Value | Unrealized P&L | Unrealized % | Realized P&L | Total P&L | AETHRON Action | Next Reassessment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Individual holdings have not yet been embedded in this static snapshot. The scheduled Robinhood MCP sync is configured to pull them automatically; the next refreshed AETHRON artifact/report should populate this table from Robinhood rather than estimated data. | ||||||||||||||
| Asset | Account | Class | Methodology | Entry Date | Exit Date | Qty | Avg Entry | Avg Exit | Realized P&L | Return % | Holding Period | Outcome | Exit Reason | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No closed-position detail is embedded yet. Robinhood realized-P&L and trade-history data will populate this section when available. | ||||||||||||||
| Timestamp | Total Value | Stocks/ETFs | Crypto | Options | Cash | Buying Power | Pending Deposit | Source |
|---|---|---|---|---|---|---|---|---|
| Aug. 21, 2026 • ~1:09 PM CT | $335.72 | $23.13 | $217.76 | $26.00 | $68.84 | $68.84 | $90.00 | Robinhood Trading MCP • verified read-only snapshot |
| # | System | Ticker | Trigger | Entry | Exit / Measure | Exit Price | Peak | Return | Outcome | Reason |
|---|
| # | System | Ticker | Instrument | Entry Date | Entry | Qty | Strike / Exp. | Exit | P&L | Return | Result |
|---|
Make a company's economics comparable, normalized and falsifiable, then measure the gap between what the stock price already assumes and what the business is likely to deliver. Bloom separates business quality from stock attractiveness: Modules 1–5 underwrite the company; Modules 6–8 underwrite the stock; Module 9 makes every run comparable.
A wonderful business can be a poor investment when the current price already requires heroic growth, margins or duration. Bloom looks for the implied vs. probable gap and forces the thesis to name in advance what would prove it wrong.
Bloom 0.3 is AETHRON's standalone deep-underwriting workspace. It can be run on any equity independently of Catalyst, Kelvin, MAX WILD, Situational Hedge 0.1 or Situational Hedge 0.2. Its job is to make every material assumption sourced, dated, normalized, mathematically explicit and falsifiable, producing a complete stock-vetting file that stands on its own.
Selection comes from the current AETHRON actionable/watch pipeline only to decide what Bloom studies first. Once a ticker enters this cohort, every prior score, technical trigger, Situational Hedge label, MAX WILD grade and Market Health opinion is quarantined from Bloom's analysis.
| # | Ticker | Company | AETHRON Intake Status | Bloom Stage | Bloom Verdict | First Bloom Question |
|---|
This replaces the prior placeholder queue. Every ticker below has a completed Bloom scorecard, expectations verdict, scenario set, falsification tripwire, confidence, data gaps and decay date. REPORTED figures come from company/SEC sources; NORMALIZED figures show Bloom adjustments; AETHRON ESTIMATE values are explicitly modeled. Data gaps remain visible rather than being fabricated.
| Bloom Rank | Ticker | Stage | Score | Expectations Decode | Current | PW Value | Expected Gap | Asymmetry | Confidence |
|---|---|---|---|---|---|---|---|---|---|
| #1 | RDDT | 9/9 COMPLETE | 87/100 | FAIR / DEMANDING | $153.95 27 AUG 2026 | $226.50 | +47.1% | 4.52x | HIGH |
| #2 | TOST Toast | 9/9 COMPLETE | 85/100 | FAIR | $35.27 28 AUG 2026 | $43.25 | +22.6% | 2.41x | HIGH |
| #3 | S SentinelOne | 9/9 COMPLETE | 74/100 | FAIR-HIGH / CASH CONVERSION REQUIRED | $22.74 27 AUG 2026 | $27.00 | +18.7% | 2.26x | MEDIUM-HIGH |
| #4 | SMCI Super Micro Computer | 9/9 COMPLETE | 74/100 | EASY–FAIR / RISK-LOADED | $37.19 28 AUG 2026 | $47.00 | +26.4% | 2.16x | MEDIUM |
| #5 | NTRA Natera | 9/9 COMPLETE | 72/100 | HEROIC | $338.70 27 AUG 2026 | $360.00 | +6.3% | 1.36x | HIGH |
| #6 | TEM Tempus AI | 9/9 COMPLETE | 68/100 | HEROIC | $70.69 27 AUG 2026 | $77.25 | +9.3% | 1.54x | MEDIUM |
| #7 | UPST Upstart | 9/9 COMPLETE | 68/100 | FAIR / CYCLE-SENSITIVE | $30.46 27 AUG 2026 | $38.40 | +26.1% | 2.37x | MEDIUM |
| #8 | RDW Redwire | 9/9 COMPLETE | 64/100 | HEROIC-LEANING | $10.80 28 AUG 2026 | $13.60 | +25.9% | 2.33x | MEDIUM |
| #9 | RLAY Relay Therapeutics | 9/9 COMPLETE | 55/100 | HEROIC / BINARY | $18.73 28 AUG 2026 | $21.35 | +14.0% | 2.24x | MEDIUM-LOW |
| #10 | RGTI Rigetti Computing | 9/9 COMPLETE | 47/100 | EXTREME HEROIC | $15.52 28 AUG 2026 | $11.55 | -25.6% | 1.38x | LOW |
Revenue = advertising $762M + other $43M = $805M in Q2. The profit engine is high-gross-margin monetization of user/community attention plus emerging data/licensing economics.
COMPLETE • BLOOM-ONLYMoat comes from community inventory, volunteer moderation and high-intent human conversation. Vulnerabilities are traffic distribution, advertiser demand, moderator/user trust and alternative social/AI discovery.
COMPLETE • BLOOM-ONLYKeep SBC as a real economic cost. A deliberately conservative economic-FCF proxy subtracts Q2 SBC from FCF: $261M − $100.95M ≈ $160M. Net dilution remained only +0.2% because buybacks offset issuance.
COMPLETE • BLOOM-ONLYReddit deserves a premium to slower social/platform peers because revenue is compounding >60% with >90% gross margin and positive FCF, but the premium still requires durable ad monetization.
COMPLETE • BLOOM-ONLYDrivers: DAU/WAU growth, ad ARPU, international monetization, search/AI licensing and expense leverage. Leading indicators: DAUq, WAUq, ad revenue growth, international revenue and gross margin.
COMPLETE • BLOOM-ONLYBloom values: $115 Bear / $220 Base / $330 Bull. Probability-weighted value $226.50 versus $153.95 snapshot; asymmetry ratio 4.52x.
COMPLETE • BLOOM-ONLYFAIR / DEMANDING rather than heroic. The current price requires strong growth, but current user/revenue/FCF evidence already supports an unusually powerful monetization curve.
COMPLETE • BLOOM-ONLYThe thesis breaks if both engagement and monetization decelerate simultaneously. The balance sheet is exceptionally strong, so business-model degradation—not solvency—is the core risk.
COMPLETE • BLOOM-ONLYComposite 87/100, #1 in Bloom Cohort 01. Highest combination of business quality, moat, balance sheet, growth durability and favorable scenario asymmetry.
COMPLETE • BLOOM-ONLY| Scenario | Per-share value | Probability | Label |
|---|---|---|---|
| BEAR | $115.00 | 20% | AETHRON ESTIMATE |
| BASE | $220.00 | 55% | AETHRON ESTIMATE |
| BULL | $330.00 | 25% | AETHRON ESTIMATE |
| PROBABILITY-WEIGHTED | $226.50 | — | AETHRON ESTIMATE |
Core economics are two engines: subscription revenue scales with locations/ARPU; fintech revenue scales with payment volume and take economics. Q2 GPV $60.7B and ARR $2.409B quantify both.
COMPLETE • BLOOM-ONLYToast sits inside restaurant workflow + payments. Dependencies include card networks/processors, merchant retention, restaurant health and competitive POS/payment platforms. Switching costs rise as more workflow modules are adopted.
COMPLETE • BLOOM-ONLYGAAP net income is positive. Bloom keeps $58M SBC/payroll as economic cost and strips the one-time ~$10M tariff-refund benefit from adjusted EBITDA when judging recurring earnings quality.
COMPLETE • BLOOM-ONLYValuation is above mature payments processors but below many high-growth SaaS platforms on recurring-growth quality. The premium is partially earned by 25% ARR growth and increasingly profitable unit economics.
COMPLETE • BLOOM-ONLYDrivers: location adds, GPV/location, subscription ARPU, fintech take economics and recurring gross-profit margin. Leading indicators: net adds, ARR growth, GPV and recurring gross profit.
COMPLETE • BLOOM-ONLY$25 Bear / $44 Base / $60 Bull; probability-weighted value $43.25 vs $35.27 current snapshot; 2.41x asymmetry.
COMPLETE • BLOOM-ONLYFAIR. The market expects durable 20%+ ecosystem growth and margin expansion, but the company already generates GAAP profit and meaningful FCF.
COMPLETE • BLOOM-ONLYJoint slowdown in location growth + GPV is the key test. Balance sheet liquidity and current profitability make solvency risk secondary.
COMPLETE • BLOOM-ONLYComposite 85/100, #2. Strong, increasingly self-funding platform economics with a less demanding expectations burden than most high-growth cohort names.
COMPLETE • BLOOM-ONLY| Scenario | Per-share value | Probability | Label |
|---|---|---|---|
| BEAR | $25.00 | 25% | AETHRON ESTIMATE |
| BASE | $44.00 | 50% | AETHRON ESTIMATE |
| BULL | $60.00 | 25% | AETHRON ESTIMATE |
| PROBABILITY-WEIGHTED | $43.25 | — | AETHRON ESTIMATE |
Subscription cybersecurity platform with ARR as the core recurring economic indicator. Q2 revenue $292M and ARR $1.218B show scale; enterprise expansion is reflected by 1,715 customers above $100K ARR.
COMPLETE • BLOOM-ONLYMoat depends on detection efficacy, endpoint/cloud/data integration, ecosystem integrations and high switching costs. Competition from CrowdStrike, Palo Alto and Microsoft is the central external threat.
COMPLETE • BLOOM-ONLYThe critical Bloom adjustment is SBC: $92.1M, ~31.5% of quarterly revenue. Bloom therefore rejects the idea that +10% non-GAAP operating margin equals mature economic profitability.
COMPLETE • BLOOM-ONLYValuation is below premium cyber leaders, partly reflecting slower growth and SBC burden. Discount can close only if ARR growth stays >20% while GAAP/owner earnings improve.
COMPLETE • BLOOM-ONLYDrivers: ARR growth, large-customer adds, net retention, gross margin, SBC/revenue and cash conversion. Leading indicators: ARR, >$100K customer count, GAAP/non-GAAP margin gap and FCF.
COMPLETE • BLOOM-ONLY$16 Bear / $27 Base / $38 Bull; probability-weighted $27 vs $22.74 snapshot; 2.26x asymmetry.
COMPLETE • BLOOM-ONLYFAIR-HIGH / CASH CONVERSION REQUIRED. Price allows upside if the platform sustains growth and turns stock-comp-heavy adjusted profits into genuine per-share owner earnings.
COMPLETE • BLOOM-ONLYARR growth <18% while SBC >25% revenue and FCF remains negative would show operating leverage is not becoming economic leverage.
COMPLETE • BLOOM-ONLYComposite 74/100, #3 by Bloom tiebreak. Moat/financial strength are strong; business-quality score is held down by SBC and GAAP losses.
COMPLETE • BLOOM-ONLY| Scenario | Per-share value | Probability | Label |
|---|---|---|---|
| BEAR | $16.00 | 25% | AETHRON ESTIMATE |
| BASE | $27.00 | 50% | AETHRON ESTIMATE |
| BULL | $38.00 | 25% | AETHRON ESTIMATE |
| PROBABILITY-WEIGHTED | $27.00 | — | AETHRON ESTIMATE |
AI/server systems are the core profit engine. Revenue is effectively systems × ASP/mix, but units/ASP are not disclosed at a level that allows a clean unit equation, so unit economics are marked UNAVAILABLE.
COMPLETE • BLOOM-ONLYCritical dependencies include accelerator/GPU supply, memory/networking, customers scaling AI clusters, manufacturing execution and liquid-cooling/data-center integration. Supplier concentration is structurally high.
COMPLETE • BLOOM-ONLYGAAP earnings already include SBC, so Bloom rejects the non-GAAP addback. Margin volatility is more important: Q4 17.5% versus FY26 10.8% means terminal-margin assumptions must be conservative.
COMPLETE • BLOOM-ONLYLow earnings/revenue multiples imply the market discounts governance, working-capital and margin risks. Unlike RGTI/NTRA, the current price does not require extreme growth assumptions.
COMPLETE • BLOOM-ONLYDrivers: AI server demand, accelerator availability, gross-margin mix, enterprise/customer mix and working-capital conversion. Leading indicators: backlog/orders, gross margin, inventory/receivables and OCF.
COMPLETE • BLOOM-ONLY$22 Bear / $48 Base / $70 Bull; probability-weighted $47 vs $37.19 snapshot; 2.16x asymmetry.
COMPLETE • BLOOM-ONLYEASY–FAIR / RISK-LOADED. The market is pricing a material risk discount despite very high revenue scale/growth; the debate is quality/durability, not whether growth exists.
COMPLETE • BLOOM-ONLYA simultaneous margin relapse and revenue slowdown invalidates the re-rating thesis. Any renewed reporting/governance issue is a separate immediate tripwire.
COMPLETE • BLOOM-ONLYComposite 74/100. Best valuation-vs-expectations score in the cohort, but quality/clarity are constrained by margin, financing and governance risk.
COMPLETE • BLOOM-ONLY| Scenario | Per-share value | Probability | Label |
|---|---|---|---|
| BEAR | $22.00 | 25% | AETHRON ESTIMATE |
| BASE | $48.00 | 50% | AETHRON ESTIMATE |
| BULL | $70.00 | 25% | AETHRON ESTIMATE |
| PROBABILITY-WEIGHTED | $47.00 | — | AETHRON ESTIMATE |
Revenue primarily comes from genetic and oncology testing. A rough blended revenue/processed-test proxy is $752.8M ÷ 1.044M ≈ $721, but this is an AETHRON ESTIMATE, not disclosed ASP, because recognition timing differs from tests processed.
COMPLETE • BLOOM-ONLYKey dependencies: payer coverage/reimbursement, clinician adoption, lab throughput, evidence generation and regulatory acceptance. Customer concentration is favorable: no individual customer >10% of six-month revenue.
COMPLETE • BLOOM-ONLYRemove $52.3M Q2 revenue-accrual true-up when assessing underlying growth; keep SBC as economic cost. Ex-true-up Q2 revenue ≈ $700.5M and still supports strong underlying growth.
COMPLETE • BLOOM-ONLYThe market assigns a very large sales multiple despite negative normalized earnings, indicating the stock is valued on oncology runway and future margin structure rather than current owner earnings.
COMPLETE • BLOOM-ONLYDrivers: oncology units, reimbursement/ASP, clinical MRD adoption, gross margin and operating leverage. Leading indicators: oncology test volume, payer coverage decisions and true-up-adjusted revenue growth.
COMPLETE • BLOOM-ONLYBloom probability-weighted value $360 from $220 Bear / $360 Base / $500 Bull versus $338.70 latest verified price.
COMPLETE • BLOOM-ONLYHEROIC. The company can be excellent while the stock still requires years of high oncology growth and substantial operating leverage to justify today’s price.
COMPLETE • BLOOM-ONLYThesis damage occurs if oncology growth falls materially, payer coverage reverses, or true-up-adjusted economics stop improving. Balance sheet is strong enough that survival is not the primary risk.
COMPLETE • BLOOM-ONLYComposite 72/100. High quality/moat/growth scores are offset primarily by valuation versus embedded expectations.
COMPLETE • BLOOM-ONLY| Scenario | Per-share value | Probability | Label |
|---|---|---|---|
| BEAR | $220.00 | 25% | AETHRON ESTIMATE |
| BASE | $360.00 | 50% | AETHRON ESTIMATE |
| BULL | $500.00 | 25% | AETHRON ESTIMATE |
| PROBABILITY-WEIGHTED | $360.00 | — | AETHRON ESTIMATE |
Revenue engine is diagnostics testing plus data/licensing. Q2 arithmetic: $289.3M Diagnostics + $93.2M Data & Apps ≈ $382.5M total. Data has the higher strategic margin potential; diagnostics supplies proprietary clinical data.
COMPLETE • BLOOM-ONLYCore dependencies: reimbursement/payers, sequencing/lab throughput, clinician adoption, data rights and integration of acquired MRD assets. Exact top-5 customer shares were not sourced, so concentration is marked UNAVAILABLE.
COMPLETE • BLOOM-ONLYSBC is kept as a real cost. The $98.5M unrealized marketable-security gain is removed from earnings. Acquisition amortization is not automatically added back until maintenance capex is separated.
COMPLETE • BLOOM-ONLYAt the latest verified snapshot the equity trades at a high single-digit EV/revenue range against still-negative normalized operating earnings. Premium requires unusually durable growth and margin expansion.
COMPLETE • BLOOM-ONLYPrimary drivers: oncology test volume, Data & Apps growth, reimbursement/ASP, gross margin, Personalis integration. Monthly leading indicators: oncology/MRD volumes, new data-license bookings, payer coverage and gross-margin trend.
COMPLETE • BLOOM-ONLYBloom scenarios imply $42 Bear / $76 Base / $115 Bull. Probability-weighted value $77.25 versus $70.69 latest verified price.
COMPLETE • BLOOM-ONLYHEROIC. Current valuation already requires diagnostics growth to remain strong while Data & Apps compounds faster and consolidated economics cross into sustained positive owner earnings.
COMPLETE • BLOOM-ONLYStress focus: integration, reimbursement, data-license growth and cash conversion. Thesis breaks if Data & Apps growth falls below 20% for two quarters or normalized burn rises materially.
COMPLETE • BLOOM-ONLYComposite 68/100. Strong moat/growth durability is offset by weak valuation-vs-expectations and incomplete normalized profitability evidence.
COMPLETE • BLOOM-ONLY| Scenario | Per-share value | Probability | Label |
|---|---|---|---|
| BEAR | $42.00 | 25% | AETHRON ESTIMATE |
| BASE | $76.00 | 50% | AETHRON ESTIMATE |
| BULL | $115.00 | 25% | AETHRON ESTIMATE |
| PROBABILITY-WEIGHTED | $77.25 | — | AETHRON ESTIMATE |
Fee-led lending marketplace: $348M of $365M Q2 revenue came from fees. A rough fee/reported-origination-volume proxy is $348M ÷ $4.2B ≈ 8.3%, but this is not a disclosed take rate and includes multiple fee streams.
COMPLETE • BLOOM-ONLYDependence on banks, credit unions, institutional funding, securitization markets, borrower demand and credit performance creates a more macro-sensitive value chain than software peers.
COMPLETE • BLOOM-ONLYGAAP net income returned positive, but SBC/payroll ~ $45.9M is larger than $16.5M GAAP net income. Bloom therefore treats current normalized owner earnings as materially below headline profit.
COMPLETE • BLOOM-ONLYRevenue multiple is modest relative to high-growth software, but that discount is deserved because earnings and volumes are cycle/funding sensitive.
COMPLETE • BLOOM-ONLYDrivers: originations, conversion/approval, funding supply, contribution margin, credit losses and secured-product economics. Leading indicators: originations, contribution margin and funding-partner/securitization activity.
COMPLETE • BLOOM-ONLY$18 Bear / $40 Base / $60 Bull; probability-weighted $38.40 versus $30.46 snapshot; 2.37x asymmetry.
COMPLETE • BLOOM-ONLYFAIR / CYCLE-SENSITIVE. Current valuation does not demand heroic multiples, but it assumes funding remains available and credit performance does not reverse growth.
COMPLETE • BLOOM-ONLYFunding withdrawal plus falling contribution margin is the central failure mode. Secured-product losses must keep converging toward breakeven.
COMPLETE • BLOOM-ONLYComposite 68/100. Attractive valuation is offset by financial-strength/funding sensitivity and less predictable normalized economics.
COMPLETE • BLOOM-ONLY| Scenario | Per-share value | Probability | Label |
|---|---|---|---|
| BEAR | $18.00 | 30% | AETHRON ESTIMATE |
| BASE | $40.00 | 45% | AETHRON ESTIMATE |
| BULL | $60.00 | 25% | AETHRON ESTIMATE |
| PROBABILITY-WEIGHTED | $38.40 | — | AETHRON ESTIMATE |
Revenue is contract/milestone driven across Space and Defense Tech; backlog is the best forward unit of demand. Q2 revenue $117.1M against $542.1M backlog provides visibility but not guaranteed margin conversion.
COMPLETE • BLOOM-ONLYGovernment/defense/civil-space awards, program execution, components, launch schedules and contract funding are key dependencies. Large-program customer concentration remains a central risk.
COMPLETE • BLOOM-ONLYNet loss remains negative and adjusted EBITDA is also negative. Acquisition accounting and share issuance must be considered because per-share value can lag enterprise growth.
COMPLETE • BLOOM-ONLYAerospace/defense-growth comps can justify premium sales multiples only if backlog converts into durable margins/FCF. Current valuation still anticipates a major profitability inflection.
COMPLETE • BLOOM-ONLYDrivers: bookings/book-to-bill, backlog conversion, Defense Tech mix, gross margin and cash burn. Leading indicators: bookings, backlog, gross margin, contract milestones and FCF.
COMPLETE • BLOOM-ONLY$6 Bear / $14 Base / $22 Bull; weighted $13.60 vs $10.80 snapshot; 2.33x asymmetry.
COMPLETE • BLOOM-ONLYHEROIC-LEANING. The stock requires backlog growth to translate into positive normalized FCF before dilution erodes the enterprise-growth story.
COMPLETE • BLOOM-ONLYBook-to-bill <1 plus declining backlog/negative FCF is the critical combination. Balance-sheet liquidity reduces near-term survival risk.
COMPLETE • BLOOM-ONLYComposite 64/100. Growth durability is attractive, but business quality and valuation confidence wait on cash conversion and per-share discipline.
COMPLETE • BLOOM-ONLY| Scenario | Per-share value | Probability | Label |
|---|---|---|---|
| BEAR | $6.00 | 30% | AETHRON ESTIMATE |
| BASE | $14.00 | 45% | AETHRON ESTIMATE |
| BULL | $22.00 | 25% | AETHRON ESTIMATE |
| PROBABILITY-WEIGHTED | $13.60 | — | AETHRON ESTIMATE |
Pre-commercial precision-medicine model. Current revenue is licensing, not product economics; unit economics for zovegalisib are UNAVAILABLE until commercialization assumptions are modeled.
COMPLETE • BLOOM-ONLYValue chain is concentrated in trial execution, regulators, clinical sites, manufacturing readiness and eventual payer access. Pipeline concentration makes zovegalisib the dominant throat-exposure.
COMPLETE • BLOOM-ONLYTraditional EBIT normalization has low explanatory value. R&D may be capitalized analytically, but cash burn remains real. The May follow-on strengthens survival while increasing share-count dilution.
COMPLETE • BLOOM-ONLYPeer comparison must use stage, probability-adjusted pipeline value and cash rather than P/E. Current enterprise value embeds major commercial success despite negligible revenue.
COMPLETE • BLOOM-ONLYDrivers: Phase 3 probability of success, regulatory design agreement, addressable breast-cancer population, launch timing and peak penetration. Leading indicators are trial enrollment/readouts and regulator feedback.
COMPLETE • BLOOM-ONLYProbability-weighted scenario value $21.35 from $7 Bear / $22 Base / $45 Bull versus $18.73 current snapshot.
COMPLETE • BLOOM-ONLYHEROIC / BINARY. The price cannot be justified by existing revenue; it requires successful late-stage clinical conversion into a multi-billion-dollar commercial asset.
COMPLETE • BLOOM-ONLYClinical efficacy/safety/regulatory setbacks are thesis-killing. 18-month survival appears strong given $910.9M liquidity, but future commercialization can still require additional capital.
COMPLETE • BLOOM-ONLYComposite 55/100. Financial runway is strong; business quality and valuation confidence remain low until clinical risk is resolved.
COMPLETE • BLOOM-ONLY| Scenario | Per-share value | Probability | Label |
|---|---|---|---|
| BEAR | $7.00 | 35% | AETHRON ESTIMATE |
| BASE | $22.00 | 45% | AETHRON ESTIMATE |
| BULL | $45.00 | 20% | AETHRON ESTIMATE |
| PROBABILITY-WEIGHTED | $21.35 | — | AETHRON ESTIMATE |
Pre-scale quantum systems/services business. Revenue $5.1M is not enough to establish stable unit economics; units × ASP is UNAVAILABLE from disclosed information.
COMPLETE • BLOOM-ONLYDependencies: technical fidelity/scale, cryogenic/superconducting hardware, government funding, research customers and eventual commercial demand. Technology roadmap is the dominant single point of failure.
COMPLETE • BLOOM-ONLYThere is no meaningful positive earnings base to normalize. Q2 operating loss is more than 5x revenue; Bloom therefore focuses on burn, liquidity and commercialization requirements.
COMPLETE • BLOOM-ONLYTraditional P/E is meaningless. Sales-based comparison shows enterprise value vastly larger than current revenue; this is venture-style terminal-option valuation in a public stock.
COMPLETE • BLOOM-ONLYDrivers: two-qubit fidelity, qubit count, system orders, government/commercial funding and burn. Leading indicators are benchmarked fidelity, shipped systems/orders and quarterly revenue.
COMPLETE • BLOOM-ONLY$5 Bear / $12 Base / $30 Bull; probability-weighted $11.55 vs $15.52 snapshot — negative expected return under current Bloom assumptions.
COMPLETE • BLOOM-ONLYEXTREME HEROIC. Current price requires a rapid transition from experimental/early-commercial revenue to scalable quantum-system economics.
COMPLETE • BLOOM-ONLYTechnical roadmap slippage plus absent commercial order growth invalidates the valuation case. Liquidity buys time but does not prove product-market economics.
COMPLETE • BLOOM-ONLYComposite 47/100, lowest in cohort. Balance sheet is strong, but current economics and valuation-vs-expectations are the major weaknesses.
COMPLETE • BLOOM-ONLY| Scenario | Per-share value | Probability | Label |
|---|---|---|---|
| BEAR | $5.00 | 45% | AETHRON ESTIMATE |
| BASE | $12.00 | 40% | AETHRON ESTIMATE |
| BULL | $30.00 | 15% | AETHRON ESTIMATE |
| PROBABILITY-WEIGHTED | $11.55 | — | AETHRON ESTIMATE |
Every value carries its source and period/date. A number without provenance is not allowed into the Bloom file.
Every figure must be tagged REPORTED, NORMALIZED, CONSENSUS or AETHRON ESTIMATE. Any adjustment must show the arithmetic.
If a figure cannot be sourced, write UNAVAILABLE and state what evidence is required. Missing data is information.
If the latest filing is more than 90 days old, Bloom flags the analysis before a conclusion is formed.
Derived values must expose the arithmetic. One visible equation has priority over narrative hand-waving.
Modules 1–5 answer whether the business is good. Modules 6–8 answer whether the stock is attractive at today's price.
Bloom does not allow vague language such as “margins may face pressure” when the effect can be expressed in revenue, margin, EPS or dollars.
Bloom does not depend on another AETHRON methodology to complete the analysis. It produces a self-contained underwriting file; any later use by another system is optional and outside the Bloom verdict.
Rebuild revenue by segment/geography, explicit unit economics, fixed/variable costs, operating leverage and cash conversion.
Map customers, suppliers, critical inputs, substitutes, pricing power and vertical-adjacency threats.
Rebuild accounting so reported profit is not mistaken for economic profit. Calculate owner earnings, invested capital and normalized ROIC.
Define explicit peer inclusion rules, compare normalized economics only, and explain every premium/discount.
Identify what actually moves EPS over the next 2–3 years and attach a leading indicator to every driver.
Each scenario uses named, numbered assumptions and produces terminal revenue, normalized EBIT, EPS, FCF and per-share value.
Reverse-engineer the current price into the revenue growth, operating margin and duration of excess returns the market is already demanding.
Name five disconfirming observables, the strongest opposing argument, insider behavior, balance-sheet stress and catalyst calendar.
Score identical dimensions 0–100 and preserve the rationale so 8–12 runs can become a real ranking instrument.
| # | Adjustment | Bloom Treatment |
|---|---|---|
| 1 | Stock-based compensation | Treat as a real economic cost; subtract from earnings and measure dilution net of buybacks. |
| 2 | R&D | Capitalize/amortize over an industry-appropriate 3–7 year economic life to expose invested capital. |
| 3 | Operating leases | Confirm post-ASC 842 balance-sheet treatment; adjust debt/EBIT where necessary. |
| 4 | Non-recurring items | Strip restructuring, impairments, litigation and one-time tax benefits with amount/date. |
| 5 | Acquisition amortization | Add back purchase-accounting intangible amortization only when maintenance capex is separately funded. |
| 6 | Inventory method | Note LIFO vs. FIFO and normalize when peer comparison requires it. |
| 7 | Pension / OPEB | Service cost → operating; interest cost → financing. |
| 8 | FX | Restate growth in constant currency. |
| 9 | Capitalized interest/software | Reconcile capitalization to the cash-flow statement. |
| 10 | Tax rate | Use cash tax rate rather than book tax rate. |
Composite Score = unweighted mean of the six standardized dimensions. Also record the single largest risk, Asymmetry Ratio = upside to bull case ÷ downside to bear case, and one Falsification Tripwire. Every run must finish with CONFIDENCE, DATA GAPS and a DECAY DATE.
| # | Ticker | Status | Note | Composite | Expectations | Tripwire | Decay Date |
|---|
0.1 and 0.2 are intentionally separate. Version 0.1 maps institutional positioning, real demand and physical supply scarcity to find structural sellers/enablers. Version 0.2 applies the Ackman transcript framework—deep research, high conviction, concentration, asymmetric protection, network effects, tollbooths and compounding cash machines—to find businesses worthy of concentrated ownership. A stock can qualify for one methodology without qualifying for the other.
Use the methodology that matches the opportunity. When both independently agree, conviction can rise—but correlation, valuation, liquidity and downside controls still govern capital.
Based directly on the supplied video transcript, Ackman’s operating pattern is: do the research, build conviction, concentrate capital, protect asymmetrically when the downside is mispriced, and prefer businesses with network effects, tollbooth economics or self-reinforcing cash machines. AETHRON 0.2 is a standalone ownership methodology. Situational Hedge 0.1 may be used as an independent cross-check when structural scarcity also exists, but a company does not need to pass 0.1 to qualify for 0.2.
Ackman’s process begins with research sufficient to form a differentiated view rather than copying consensus or owning a theme casually.
AETHRON TEST → Can we state the consensus assumption, our contradiction, the evidence and what would prove us wrong?The transcript frames Ackman as researching, building conviction and then betting big. AETHRON therefore distinguishes a researched idea from an idea strong enough to deserve meaningful capital.
AETHRON TEST → Are catalyst, business economics, positioning and downside all strong enough to justify concentration?The transcript describes nearly all portfolio capital concentrated in a handful of companies. AETHRON imports the principle, not blind concentration: position size rises with evidence and falls with correlation, volatility and uncertainty.
AETHRON TEST → If this became a top-5 position, do we understand the true correlated exposure and maximum loss?The COVID example in the transcript shows the power of paying a limited premium for convex protection when collapse risk is badly underpriced. The hedge is a separate expression of the risk thesis—not permanent portfolio drag.
AETHRON TEST → Can a defined-risk hedge protect a concentrated book at an acceptable cost if the regime breaks?The five young companies we screen next do not need to look like mature Pershing holdings today. They must show credible evidence that they can become one of the three archetypes:
The transcript does not provide a numerical formula, so these weights are an AETHRON implementation, not an Ackman quote:
This scan deliberately rejects microcap lottery tickets. The universe is early-public U.S.-listed platforms still in their scaling phase, with strong liquidity, generally 20%+ core operating growth, improving cash economics and a credible path to a Network Effect, Tollbooth or Compounding Cash Machine. Passing this board earns research status—not an automatic buy.
| Rank | Stock | 0.2 Score | Primary Archetype | Route | Current Action |
|---|---|---|---|---|---|
| 1 | RDDT • Reddit | 92 | Network Effect + Cash Machine | CONCENTRATED CORE WATCH | WAIT FOR ENTRY • DO NOT CHASE |
| 2 | FIG • Figma | 90 | Network Effect + Recurring Cash | CONCENTRATED CORE WATCH | WAIT FOR POST-IPO BASE |
| 3 | TOST • Toast | 88 | Tollbooth + Cash Machine | CONCENTRATED CORE WATCH | WAIT FOR BASE / BREAKOUT |
| 4 | IOT • Samsara | 86 | Recurring Cash Machine + Data Moat | CONCENTRATED CORE WATCH | WAIT FOR BASE + RECLAIM |
| 5 | CRCL • Circle | 83 | Tollbooth + Network Effect | EMERGING COMPOUNDER | WAIT FOR ARC / DEFINED SUPPORT |
Why it fits: every additional community, contributor and reader deepens the corpus of human conversation, increases discovery value and expands monetizable attention. The unusually high gross margin and rapidly scaling free cash flow create the beginnings of a reinvestment machine.
Catalyst: international monetization, ad-product expansion and monetization of Reddit’s differentiated human-data corpus. Primary risk: valuation/repricing, search-distribution dependence and platform moderation/regulatory issues.
Why it fits: collaboration becomes more useful as designers, developers, product managers and enterprises standardize on one shared canvas. Expansion economics are visible in 136% NDR, while AI credits add a new monetization layer on top of seats.
Catalyst: full-stack creation, Figma Make / agents and continued AI-credit monetization. Primary risk: premium valuation, post-IPO supply and GAAP operating losses while investment remains high.
Why it fits: Toast sits directly in the restaurant transaction flow. Its own filing states that as customers generate more sales and GPV, Toast generally earns more fintech revenue. Software + payment processing makes the platform a commerce tollbooth with recurring cross-sell economics.
Catalyst: continued location growth, enterprise penetration and AI-driven product expansion. Primary risk: restaurant cyclicality, payment competition and lower FCF versus the prior-year quarter.
Why it fits: recurring software revenue grows as customers connect more vehicles, equipment, workers and workflows. The strongest Ackman fit is not a classical cross-customer network effect; it is a sticky operating-data platform whose expanding product surface can compound ARR and cash flow.
Catalyst: Operational AI / AI Agents and accelerating large-enterprise expansion. Primary risk: premium software multiple, hardware/device exposure and competition from telematics/industrial software incumbents.
Why it fits: USDC and Circle Payments Network can become settlement tollbooths if more institutions, applications and agents standardize on them. More liquidity, integrations and validators can reinforce utility. This is the highest-upside but least mature Ackman-quality candidate in the five.
Catalyst: Arc public mainnet scheduled for Sept. 16, institutional validator/integration growth and agentic payments. Primary risk: reserve income was $668M of $701M total revenue/reserve income in Q2, leaving earnings highly sensitive to interest rates, regulation and stablecoin competition.
SEC 13F source of record. Resolve CUSIPs. Preserve puts/calls as context, not copy orders.
New / added / reduced / exited across quarters. Static weight alone is insufficient.
Hyperscaler capex, guidance direction, customer orders and quoted physical constraints.
Grid, turbines, transformers, memory, foundry/packaging, cooling, fiber and networking scarcity.
Seller / Enabler / Victim / Neutral / Unscored. Only monetizable scarcity earns positive edge.
Systems 01, 02, 05 and 06 test catalyst, repricing, skew and market health.
Freshness, concentration, correlation, volatility, liquidity, event and leverage penalties.
SIMPLE ACTION + staged entry. No margin. Preflight and explicit approval before any order.
| # | Ticker / company | Scarcity lane | Supply 0–5 | Verified dislocation | 0–180d contradiction catalyst / consensus error | MAX WILD | Route |
|---|---|---|---|---|---|---|---|
| 1 | COHU Cohu | AI/HPC semiconductor test + precision thermal control | 4 / 5 | 8.11M shares short; ~17.7% float; ~7.2 days to cover | Q2 sales +38% YoY, test-cell utilization ~80%, direct next-gen AI datacenter processor orders. Bear case assumes semi-cap demand rolls before AI test intensity scales. | 92 • ELITE | SYSTEM 04 PRIORITY |
| 2 | CAMT Camtek | Advanced packaging / HBM inspection & metrology | 5 / 5 | 2.68M shares short; ~9.4% float on FINRA-based float data; ~5.4 DTC | YTD orders >$600M; Advanced Packaging revenue guided ~+70% Q1→Q4; >$105M HBM/OSAT AI orders. Error: advanced-packaging capex peaks before backlog converts. | 91 • ELITE | SYSTEM 04 PRIORITY |
| 3 | POWL Powell Industries | Switchgear / electrical distribution / behind-the-meter power | 5 / 5 | 2.73M shares short; ~7.7% float; short interest +14% vs prior report | Record $934M quarterly orders, $2.4B backlog, >$400M data-center order. Error: industrial cycle fade overwhelms the structurally undersupplied power build. | 90 • ELITE | SYSTEM 04 PRIORITY |
| 4 | AMRC Ameresco | Grid-queue bypass / behind-the-meter generation | 5 / 5 | 4.48M shares short; ~15.4% float; ~8.2 DTC; ~$1B+ gate only narrowly cleared | $1.2B of Q2 data-center awards; Power Infrastructure awarded backlog $4.4B. Key catalyst is awards converting to contracted backlog / construction milestones. Financing and execution are the principal veto risks. | 89 • STRONG | SYSTEM 04 |
| 5 | AAON AAON | Data-center cooling / custom air-side & liquid thermal systems | 5 / 5 | ~5.9% float short; market cap roughly halved from its 2026 peak while operating backlog expanded | Q2 sales +101%, total backlog $2.0B (+98% YoY), BASX backlog +185%. Error: recent de-rating assumes capacity/ramp risk outweighs hyperscale cooling demand. | 89 • STRONG | SYSTEM 04 |
| 6 | AMSC American Superconductor | Grid reliability / power-quality / utility interconnection equipment | 4 / 5 | 3.53M shares short; ~7.6% float; stock materially below 2026 peak | Quarterly orders >$130M; 12-month backlog >$300M; Grid generated ~81% of revenue. Error: de-rating treats bookings as cyclical rather than a grid-capacity scarcity signal. | 88 • STRONG | SYSTEM 04 |
| 7 | MOD Modine | Data-center thermal management / cooling capacity | 5 / 5 | 3.46M shares short; ~6.6% float; short interest +22% vs prior report | Data Centers sales +90% YoY and backlog nearly doubled; current supply constraints are limiting production. Error: bottlenecks are read as lost demand instead of temporary inability to ship into strong demand. | 86 • STRONG | SYSTEM 04 |
| 8 | BELFB Bel Fuse | Power conversion / magnetics / high-speed connectivity | 4 / 5 | ~6.6% float short; short interest +9.6% vs prior report | Industrial Technology & Data Solutions sales +31% YoY. Error: market treats data-center power/connectivity acceleration as a temporary mix tailwind after a large prior rerating. | 84 • WATCH | PROOF TRANCHE ONLY |
| 9 | ACLS Axcelis | Ion implantation / memory & power semiconductor fab capacity | 4 / 5 | ~5.2% float short, down sharply from ~12% in March — crowd has already partially capitulated | Robust memory demand, $452M backlog and ~$230M Q3 revenue guide; pending Veeco combination is an event catalyst. Lower rank because the short-dislocation has already compressed. | 83 • WATCH | WAIT FOR NEW DISLOCATION |
| 10 | GNRC Generac | On-site generation / speed-to-power for data centers | 5 / 5 | ~3.5% float short; low squeeze fuel, but shares remain well below the mid-2026 peak | Data-center backlog reported near $1.6B; $250M capacity expansion; C&I sales +29%. Error: legacy residential-generator framing may underweight an emerging data-center power business. | 82 • WATCH | CATALYST CONFIRMATION |
| Ticker / Asset | Reported value | Approx. filing weight | AETHRON interpretation | Current use |
|---|---|---|---|---|
| SNDK • Sandisk | $5.67B | ~28.0% | Memory / storage scarcity thesis | Historical thesis evidence |
| MU • Micron | $5.57B | ~27.5% | HBM / memory scarcity thesis | Historical thesis evidence |
| BE • Bloom Energy | $1.90B stock + call | ~9.4% stock | Power availability / onsite generation | Re-score independently |
| TSM • Taiwan Semi | $1.27B stock + call | ~6.3% stock | Leading-edge foundry / packaging | Re-score independently |
| NBIS • Nebius | $1.23B | ~6.1% | AI compute infrastructure | Re-score independently |
| CRWV • CoreWeave | $744.5M | ~3.7% | AI compute / data-center demand | Already in AETHRON • fresh gate required |
| CORZ • Core Scientific | $665.6M | ~3.3% | Power + data-center capacity | Re-score independently |
| STM • STMicroelectronics | $584.3M | ~2.9% | Semiconductor exposure | Needs gap-side proof |
| APLD • Applied Digital | $469.0M | ~2.3% | Data-center / power-land capacity | Already in AETHRON • fresh gate required |
| IREN • IREN | $433.3M | ~2.1% | Power + AI/HPC capacity | Already in AETHRON • fresh gate required |
The PDF starts from the latest 13F. AETHRON adds a Freshness Gate and Live-Event Override. A forced sale, financing event, thesis break or management warning after period-end can zero out the filing's execution value.
The PDF allows up to 20% per position. AETHRON sizes by volatility, liquidity, health score and correlation. Default single-name risk budget is ≤12.5%; correlated theme exposure is ≤30%, both configurable downward.
SNDK + MU represented roughly 55.6% of the Q2 filing. AETHRON treats economically linked holdings as a single risk cluster and penalizes the entire cluster before sizing.
A held put/call is excluded from automatic sizing because intent can be hedge, spread or directional. System 05 Skew Map independently measures option-market positioning before any options execution.
Even the perfect bottleneck seller can be a bad trade after a vertical repricing. Kelvin 0.2 checks remaining repricing, relative volume, support, catalyst timing and chase risk.
If AETHRON's active book becomes crowded in one macro/theme factor, Situational Hedge raises the HEDGE REQUIRED flag and routes the exposure to System 05 for defined-risk protection analysis rather than increasing gross leverage.
The PDF suggests market-day buys after approval. AETHRON preserves explicit review but defaults to its existing limit-order, no-margin, no-chase execution discipline.
Every scored name is tracked at T+5, T+20 and T+60. Demand, supply, smart-money and risk weights change only after enough observed signals — not because one trade worked or failed.
13F age >45 days from period end, or a material post-period event, forces HISTORICAL ONLY.
Correlated AI/memory/power names are aggregated. Theme risk >30% triggers CUT / HEDGE.
Situational Hedge uses settled capital, not margin buying power. Borrowed exposure is prohibited by default.
Illiquid or binary names get lower caps; catalyst gaps can override every other score.
PDF methodology: “Bootleg a hedge fund” — demand score, supply score, gap-side classification and approval-based execution were adapted as inputs, not copied as final AETHRON rules.
Primary filing: SEC Form 13F-HR, Situational Awareness LP, period ended 2026-06-30, filed 2026-08-14. Open SEC filing ↗
Live-event override: credible August 2026 reporting on the fund's July drawdown and public-equity de-risking means the June 30 filing is not treated as a current position list.
Execution rule: Situational Hedge is decision support. It creates a preferred position, trigger, hedge requirement and risk budget; it does not authorize an order by itself.